INMUNE BIO INC. Research and Development in Process
INMUNE BIO INC. (INMB) reported Research and Development in Process of $18.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-02
- INMUNE BIO INC. research and development in process for fiscal 2022 was $18.00K, a 99.24% decline from fiscal 2021.
- INMUNE BIO INC. research and development in process for fiscal 2021 was $2.37M, a 219.68% increase from fiscal 2020.
- INMUNE BIO INC. research and development in process for fiscal 2020 was $742.00K.
| Period end | Research and Development in Process 12 month |
|---|---|
| 2022-12-31 | $18.00K 10-K · filed 2023-03-02 |
| 2021-12-31 | $2.37M 10-K · filed 2023-03-02 |
| 2020-12-31 | $742.00K 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |